Drugs / MSP1 42-C1
last change Jan 2010 re-read 2 minutes ago

MSP1 42-C1

Vaccine

Developed for
malaria
Investigated by
Johns Hopkins Bloomberg School of Public Health · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00320658 Mar 2006 → Jul 2007 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MSP1(42)-C1 “FVO and 3D7 recombinant proteins of MSP1(42) were mixed (MSP1(42)-C1).” PMID 20107498 Jan 2010
1

NCT00320658

Modality Vaccine “MSP1 42-C1 is a malaria vaccineNCT00320658
Route Intramuscular “3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm.” NCT00320658